Lv4
750 积分 2024-03-29 加入
Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation
1天前
已完结
Systematic Review: Targeting HER2 in Bladder Cancer
6天前
已完结
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
6天前
已完结
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
6个月前
已完结
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
7个月前
已完结
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
7个月前
已完结
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice
7个月前
已完结
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
8个月前
已完结
德曲妥珠单抗临床管理路径及不良反应处理中国专家共识（2024版）
9个月前
已完结
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
9个月前
已完结
皖公网安备34019202002308
